Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/01/2005CA2556818A1 Methods to relief pain
09/01/2005CA2556810A1 Skincare compositions comprising salicylic acid
09/01/2005CA2556589A1 4-substituted piperidine derivatives
09/01/2005CA2556550A1 Cytotoxin compound and method of isolation
09/01/2005CA2556503A1 Topical formulations for the treatment of skin conditions
09/01/2005CA2556480A1 Pyrimidine derivatives and use thereof as agricultural and horticultural fungicides
09/01/2005CA2556447A1 Terephthalamide peptidomimetic compounds and methods
09/01/2005CA2556425A1 Methods of modulating il-23 activity; related reagents
09/01/2005CA2556424A1 Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites
09/01/2005CA2556423A1 Piperazine derivatives for the treatment of endometriosis
09/01/2005CA2556350A1 Prodrugs of substituted amino heterobicycles which modulate the function of the vanilloid-1 receptor (vr1)
09/01/2005CA2556320A1 Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists for the treatment of gastrointestinal disorders
09/01/2005CA2556270A1 2-substituted and 4-substituted aryl nitrone compouds
09/01/2005CA2556268A1 Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005CA2556263A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005CA2556229A1 System immune activation method using non cpg nucleic acids
09/01/2005CA2556216A1 Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
09/01/2005CA2556214A1 Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
09/01/2005CA2556160A1 Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
09/01/2005CA2555970A1 Therapeutic amide derivatives
09/01/2005CA2555814A1 Alpha-(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
09/01/2005CA2555774A1 Compression-coated tablets and manufacture thereof
09/01/2005CA2555737A1 Schizochytrium fatty acid synthase (fas) and products and methods related thereto
09/01/2005CA2555641A1 Drug conjugates
09/01/2005CA2555409A1 Novel sulfone amide derivative
09/01/2005CA2555406A1 Improved therapy using a combination of raloxifene and alendronate
09/01/2005CA2555402A1 Bipyridyl amides as modulators of metabotropic glutamate receptor-5
09/01/2005CA2555399A1 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
09/01/2005CA2555386A1 Use of cholinesterase inhibitors for treating vascular depression
09/01/2005CA2555383A1 Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
09/01/2005CA2555272A1 Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005CA2555263A1 Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
09/01/2005CA2555261A1 Management of ophthalmologic disorders, including macular degeneration
09/01/2005CA2555133A1 Substituted quinoline compounds
09/01/2005CA2555084A1 Combinatorial therapy with an acetylcholinesterase inhibitor and (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate
09/01/2005CA2555073A1 Amino heterocyclic modulators of chemokine receptor activity
09/01/2005CA2555071A1 Histamine-3 receptor modulators
09/01/2005CA2554894A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists
09/01/2005CA2554774A1 Novel heterocyclic compound
09/01/2005CA2554695A1 Solid formulations of ospemifene
09/01/2005CA2554686A1 Compounds
09/01/2005CA2554310A1 Benzamide derivatives and their use as glucokinase activating agents
09/01/2005CA2554090A1 Triazole derivatives which inhibit vasopressin antagonistic activity
09/01/2005CA2554040A1 Use of meloxicam for the treatment of respiratory diseases in pigs
09/01/2005CA2553696A1 Indazole-carboxamide compounds as 5-ht4 receptor agonists
09/01/2005CA2553369A1 Pharmaceutical compositions based on anticholinergics and pegsunercept
09/01/2005CA2553367A1 Composition for treating a dermatological inflammatory response and method of preparation thereof
09/01/2005CA2553189A1 Use of a compound modifying an interleukin 5, interleukin 6 and/or interleukin 10 secretion for preparing a pharmaceutical composition for rosacea treatment
09/01/2005CA2553188A1 Use of a compound modulating at least one receiver selected in a group comprising an interleukin 8 type b receptor and pacap-1 receptor for preparing a pharmaceutical composition for rosacea treatment
09/01/2005CA2552939A1 New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins
09/01/2005CA2552903A1 Pharmaceutical compositions based on anticholinergics and pegsunercept
09/01/2005CA2552902A1 Multilayer tablet
09/01/2005CA2552433A1 Cinnamic amides, process for their preparation, and pharmaceutical compositions containing them
09/01/2005CA2552430A1 Novel benzofurans and indols
09/01/2005CA2552094A1 Amidine derivatives for treating amyloidosis
09/01/2005CA2548218A1 Imidazole-based hmg-coa reductase inhibitors
09/01/2005CA2540921A1 The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic ass peptides in amyloidopathies
09/01/2005CA2540598A1 Pyrazolopyridines and analogs thereof
09/01/2005CA2537079A1 Fluorene derivative
09/01/2005CA2526905A1 Composition for nkt cell activation
09/01/2005CA2498966A1 Novel pyrazole analogs acting on cannabinoid receptors
09/01/2005CA2498644A1 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (no) production
08/2005
08/31/2005EP1568781A2 Melanogenesis-modulating macrolides assessed by mammalian cell based activity assays
08/31/2005EP1568779A1 HSV strains for the oncolytic treatment of cancer
08/31/2005EP1568772A2 Human growth hormone variants
08/31/2005EP1568771A2 Human growth hormone variants
08/31/2005EP1568708A2 Methods and medical uses of nucleic acids encoding a TRAF inhibitor
08/31/2005EP1568706A1 Novel steroid agonist for FXR
08/31/2005EP1568697A1 1,3-benzothiazinone derivatives, process for producing the same and use thereof
08/31/2005EP1568695A1 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same
08/31/2005EP1568692A1 (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors
08/31/2005EP1568691A1 Erythropoietin production accelerator
08/31/2005EP1568690A1 The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers
08/31/2005EP1568688A1 Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient
08/31/2005EP1568685A1 Aminoadamantane derivatives as therapeutic agents
08/31/2005EP1568383A2 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
08/31/2005EP1568382A1 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER
08/31/2005EP1568381A1 Remedy for hormone-dependent cancer
08/31/2005EP1568380A1 Preventive or remedy for diseases caused by hyperglycemia
08/31/2005EP1568372A1 Administration of enoxaparin sodium to patients with severe renal impairment
08/31/2005EP1568371A1 Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate
08/31/2005EP1568370A1 Topical antibacterial formulations
08/31/2005EP1568369A1 Use of meloxicam for the treatment of respiratory diseases in pigs
08/31/2005EP1568368A1 Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
08/31/2005EP1568367A1 Compounds effecting glucokinase
08/31/2005EP1568366A1 Antifungal and/or antimycotic external preparation for nail comprising neticonazole
08/31/2005EP1568365A1 Warm poultice
08/31/2005EP1568364A1 Osteogenesis promoter containing beta-cryptoxanthin as the active ingredient
08/31/2005EP1568361A2 Sustained-release pharmaceutical composition containing tamsulosin
08/31/2005EP1568359A1 Drug delivery system using subconjunctival depot
08/31/2005EP1568285A1 Agent for inhibiting rise in blood glucose level, agent for inhibiting body fat accumulation and edible material
08/31/2005EP1567869A1 Method for screening for compounds as potential sedatives or anxiolytics
08/31/2005EP1567674A2 Target for therapy of cognitive impairment
08/31/2005EP1567667A1 Treatment of huntington's disease with epa
08/31/2005EP1567644A2 Tissue specific genes and gene clusters
08/31/2005EP1567546A2 Aza-peptides
08/31/2005EP1567539A2 Allele-specific rna interference
08/31/2005EP1567533A2 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
08/31/2005EP1567529A2 Pseudopolymorphic forms of a hiv protease inhibitor
08/31/2005EP1567524A1 Thia-epothilone derivatives for the treatment of cancer
1 ... 4559 4560 4561 4562 4563 4564 4565 4566 4567 4568 4569 4570 4571 4572 4573 4574 4575 4576 4577 4578 4579 ... 7860